Adjuvant erlotinib versus placebo in patients with stage IB-IIIA nonsmall-cell lung cancer (RADIANT): A randomized, double-blind, Phase III trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Erlotinib Hydrochloride
  • Lung Neoplasms

abstract

  • Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

publication date

  • December 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.61.8918

PubMed ID

  • 26324372

Additional Document Info

start page

  • 4007

end page

  • 14

volume

  • 33

number

  • 34